Sept 30 (Reuters) - Telehealth firm LifeMD ( LFMD ) said

on Tuesday it would partner with Novo Nordisk to

offer its diabetes drug Ozempic at $499 per month to eligible

U.S. patients, including insured people whose plans do not cover

GLP-1 therapies.

Novo offers Ozempic for $499 a month to eligible cash-paying

patients via its own pharmacy, NovoCare, and through tie-ups

with telehealth platforms.

Patients can book virtual visits, complete testing and get

medicine shipped with order tracking through LifeMD ( LFMD ).